Literature DB >> 28839707

A hard act to swallow: modern management of eosinophilic oesophagitis.

John Richard Louis-Auguste1, Jonathan Hoare1.   

Abstract

Eosinophilic oesophagitis (EO) is now established as an important cause of oesophageal symptoms. It is presumed to result from eosinophilic activation to dietary antigens, which is limited to the oesophagus. Inflammatory strictures and secondary dysmotility are common and contribute to symptomatology. Current management involves food exclusion diets and swallowed topical steroid. Strictures may require endoscopic dilatation. Relapse is common but strategies for maintaining remission are not well described. Here we describe a patient with severe stricturing EO, whose symptoms were significantly exacerbated by secondary oesophageal spasm. His symptoms were refractory to dietary, endoscopic and medical therapy including parenteral corticosteroid but responded dramatically to diltiazem. Remission was eventually achieved and maintained with azathioprine, and he was able to discontinue the other therapies and relax his dietary restrictions. We discuss the evidence for dietetic, endoscopic and pharmacological interventions for this disease.

Entities:  

Keywords:  Dietary Factors; Dysphagia; Endoscopic Procedures; Oesophageal Motility Disorder; Oesophagitis

Year:  2012        PMID: 28839707      PMCID: PMC5369789          DOI: 10.1136/flgastro-2012-100238

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  15 in total

Review 1.  A systematic review of the risk of perforation during esophageal dilation for patients with eosinophilic esophagitis.

Authors:  John William Jacobs; Stuart Jon Spechler
Journal:  Dig Dis Sci       Date:  2010-03-18       Impact factor: 3.199

2.  Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis.

Authors:  Amir F Kagalwalla; Timothy A Sentongo; Sally Ritz; Therese Hess; Suzanne P Nelson; Karan M Emerick; Hector Melin-Aldana; B U K Li
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07-21       Impact factor: 11.382

3.  Eosinophilic esophagitis: a 10-year experience in 381 children.

Authors:  Chris A Liacouras; Jonathan M Spergel; Eduardo Ruchelli; Ritu Verma; Maria Mascarenhas; Edisio Semeao; Jonathan Flick; Janice Kelly; Terry Brown-Whitehorn; Petar Mamula; Jonathan E Markowitz
Journal:  Clin Gastroenterol Hepatol       Date:  2005-12       Impact factor: 11.382

Review 4.  Eosinophilic esophagitis: allergic contribution, testing, and management.

Authors:  Amindra A Arora; Catherine R Weiler; David A Katzka
Journal:  Curr Gastroenterol Rep       Date:  2012-06

5.  Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis.

Authors:  Alfredo J Lucendo; Livia C De Rezende; Susana Jiménez-Contreras; Jose Luis Yagüe-Compadre; Jesús González-Cervera; Teresa Mota-Huertas; Danila Guagnozzi; Teresa Angueira; Sonia González-Castillo; Angel Arias
Journal:  Dig Dis Sci       Date:  2011-06-15       Impact factor: 3.199

6.  Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Jonathan M Spergel; Marc E Rothenberg; Margaret H Collins; Glenn T Furuta; Jonathan E Markowitz; George Fuchs; Molly A O'Gorman; Juan Pablo Abonia; James Young; Timothy Henkel; H Jeffrey Wilkins; Chris A Liacouras
Journal:  J Allergy Clin Immunol       Date:  2011-12-28       Impact factor: 10.793

Review 7.  Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors:  Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2011-04-07       Impact factor: 10.793

8.  Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission.

Authors:  Peter Netzer; Juergen M Gschossmann; Alex Straumann; Alexander Sendensky; Rosemarie Weimann; Alain M Schoepfer
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-10       Impact factor: 2.566

9.  Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children.

Authors:  Elizabeth T Schaefer; Joseph F Fitzgerald; Jean P Molleston; Joseph M Croffie; Marian D Pfefferkorn; Mark R Corkins; Joel D Lim; Steven J Steiner; Sandeep K Gupta
Journal:  Clin Gastroenterol Hepatol       Date:  2008-02       Impact factor: 11.382

10.  Manometric findings in adult eosinophilic oesophagitis: a study of 12 cases.

Authors:  Alfredo J Lucendo; Pilar Castillo; Sonia Martín-Chávarri; Gemma Carrión; Ramón Pajares; Juan M Pascual; Noemí Manceñido; José C Erdozain
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-05       Impact factor: 2.566

View more
  2 in total

Review 1.  Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters.

Authors:  Matthew A Rank; Rajiv N Sharaf; Glenn T Furuta; Seema S Aceves; Matthew Greenhawt; Jonathan M Spergel; Yngve T Falck-Ytter; Evan S Dellon
Journal:  Ann Allergy Asthma Immunol       Date:  2020-05       Impact factor: 6.347

2.  Technical Review on the Management of Eosinophilic Esophagitis: A Report From the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters.

Authors:  Matthew A Rank; Rajiv N Sharaf; Glenn T Furuta; Seema S Aceves; Matthew Greenhawt; Jonathan M Spergel; Yngve T Falck-Ytter; Evan S Dellon
Journal:  Gastroenterology       Date:  2020-05       Impact factor: 33.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.